Novo Nordisk's RNA Deal with Korro Bio: A $530M Collaboration on Cardiomatabolic Targets
Monday, 16 September 2024, 06:40
Advancements in RNA Therapies
In a noteworthy development, Novo Nordisk has signed a major deal with Korro Bio involving $530 million in biobucks. This collaboration aims to push the frontiers of RNA therapies by targeting specific cardiometabolic diseases.
Details of the Agreement
- Two key cardiometabolic targets identified for research.
- Strategic investment aimed at accelerating innovation in treatment.
- Strengthening Novo Nordisk's position in the biotech sector.
The partnership showcases an enduring commitment to enhancing solutions for chronic diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.